We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -20.00% | 0.10 | 0.05 | 0.15 | 0.125 | 0.075 | 0.125 | 7,964,210 | 16:07:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.27 | 453.89k |
TIDMBYOT
RNS Number : 7598L
Byotrol PLC
31 December 2018
31 December 2018
Byotrol plc
("Byotrol", the "Group" or the "Company")
GRANT OF OPTIONS
Byotrol plc, the AIM listed anti-microbial technology company, announces that on 28 December 2018 it granted a total of 3,000,000 options over the Company's ordinary shares of 0.25 pence each ("Options" and "Ordinary Shares" respectively) under the Company's existing Enterprise Management Incentive Scheme to a PDMR and to an employee of the Company.
Some of the Options are being granted to a PDMR of the Company ("PDMR Options") and are detailed below:
Position No. of New No. of Options Shareholding Options Granted held post in existing Ordinary grant Shares in the Company MD, Medimark Scientific Richard Hayman Ltd 2,000,000 2,000,000 8,080,235 (PDMR)
The Options, all of which are exercisable at 2 pence per Ordinary Share over a five year period, vest on varying dates and vest in 5 tranches subject to certain share price performance targets and other performance metrics. The Options expire on 28 June 2024.
Following the grant of the 3,000,000 Options, there will be 39,248,250 Options in issue representing 9.1% per cent. of the Company's issued share capital.
Enquiries:
Byotrol plc 01925 742 000
David Traynor - Chief Executive
finnCap Ltd 020 7220 0500
Geoff Nash / Kate Bannatyne - Corporate Finance
Richard Chambers - ECM
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.
Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
Accordingly, the Company makes the following notification in accordance with the EU Market Abuse Regulation (No 596/2014):
Details of the person discharging managerial responsibilities / person closely associated a) Name Richard Hayman ------------------------------- ------------------------------------------ Reason for the Notification --------------------------------------------------------------------------- a) Position/status MD, Medimark Scientific Limited ------------------------------- ------------------------------------------ b) Initial notification/Amendment Initial ------------------------------- ------------------------------------------ 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --------------------------------------------------------------------------- a) Name Byotrol Plc ------------------------------- ------------------------------------------ b) LEI 213800AJMTSTIPA59A34 ------------------------------- ------------------------------------------ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------------------- a) Description of the ordinary shares of 0.25p each ("Ordinary Financial instrument, Shares") type of instrument Identification code GB00B0999995 ------------------------------- ------------------------------------------ b) Nature of the transaction Award of Options over Ordinary Shares ------------------------------- ------------------------------------------ c) Price(s) and volume(s) Volume - 2,000,000 Exercise Price - 2 pence ------------------------------- ------------------------------------------ d) Aggregated information: See 4c) above ------------------------------- ------------------------------------------ e) Date of the transaction 28 December 2018 ------------------------------- ------------------------------------------ f) Place of the transaction Outside of a trading venue ------------------------------- ------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHPGGPCPUPRGAR
(END) Dow Jones Newswires
December 31, 2018 02:00 ET (07:00 GMT)
1 Year Byotrol Chart |
1 Month Byotrol Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions